Retinal vein occlusion - Pipeline Insight, 2021

July 2021 | 60 pages | ID: RA62A6BFFBBEN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Retinal vein occlusion - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal vein occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Retinal vein occlusion Understanding

Retinal vein occlusion: Overview

Retinal vein occlusions occur when there is a blockage of veins carrying blood with needed oxygen and nutrients away from the nerve cells in the retina. A blockage in the retina’s main vein is referred to as a central retinal vein occlusion (CRVO), while a blockage in a smaller vein is called a branch retinal vein occlusion (BRVO). Most BRVOs occur at an arteriovenous crossing—an intersection between a retinal artery and vein. These vessels share a common sheath (connective tissue), so when the artery loses flexibility, as with atherosclerosis (hardening of the arteries), the vein is compressed. BRVO causes a sudden, painless loss of vision. If the affected area is not in the center of the eye, BRVO can go unnoticed with no symptoms.

'Retinal vein occlusion - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinal vein occlusion pipeline landscape is provided which includes the disease overview and Retinal vein occlusion treatment guidelines. The assessment part of the report embraces, in depth Retinal vein occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinal vein occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Retinal vein occlusion R&D. The therapies under development are focused on novel approaches to treat/improve Retinal vein occlusion.

Retinal vein occlusion Emerging Drugs Chapters

This segment of the Retinal vein occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinal vein occlusion Emerging Drugs

• Brolucizumab: Novartis

Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Retinal vein occlusion (RVO).

• KSI-301: Kodiak Sciences

KSI-301 is currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed towards a once every two months or longer treatment regimen.

Further product details are provided in the report……..

Retinal vein occlusion: Therapeutic Assessment

This segment of the report provides insights about the different Retinal vein occlusion drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Retinal vein occlusion

There are approx. 15+ key companies which are developing the therapies for Retinal vein occlusion. The companies which have their Retinal vein occlusion drug candidates in the most advanced stage, i.e. phase III include, Novartis.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Retinal vein occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinal vein occlusion: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinal vein occlusion therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinal vein occlusion drugs.

Retinal vein occlusion Report Insights

• Retinal vein occlusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Retinal vein occlusion Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Retinal vein occlusion drugs?
• How many Retinal vein occlusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinal vein occlusion?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinal vein occlusion therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Retinal vein occlusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Kodiak Sciences
• EyePoint Pharmaceuticals
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Ripple Therapeutics Pty Ltd
• Aerpio Pharmaceuticals
• Taiwan Liposome Company
• Graybug Vision
• Outlook Therapeutics
• Roche
• AsclepiX Therapeutics, Inc.
• PANOPTES PHARMA

Key Products

• Brolucizumab
• KSI 301
• Vorolanib intravitreous
• 601-A
• IBE-814
• AKB-9778
• TLC399
• GB-102
• ONS-5010
• Faricimab
• AXT107

Contents

Introduction
Executive Summary
Retinal vein occlusion: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  Comparative Analysis
Brolucizumab: Novartis
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
GB-102: GrayBug Vision
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..

Early Stage Products (Phase I)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  Comparative Analysis
EYP-1901: EyePoint Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
  Comparative Analysis
Retinal vein occlusion Key Companies
Retinal vein occlusion Key Products
Retinal vein occlusion- Unmet Needs
Retinal vein occlusion- Market Drivers and Barriers
Retinal vein occlusion- Future Perspectives and Conclusion
Retinal vein occlusion Analyst Views
Retinal vein occlusion Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Retinal vein occlusion
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Retinal vein occlusion
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products